08.02.48, Papzimeos (zopapogene imadenovec-drba)
Summary
Independence Blue Cross has published a new medical policy (08.02.48) effective 08/03/2026 covering Papzimeos (zopapogene imadenovec-drba) for treatment of recurrent respiratory papillomatosis (RRP) in adults. Coverage is limited to a single lifetime treatment course of four injections over 12 weeks when specific clinical criteria are met, including confirmed HPV 6/11 diagnosis, prior surgical intervention, and prescriber attestation of surgical debulking protocols. Billing teams must implement prior authorization requirements and ensure claims are submitted only when all medical necessity criteria are documented.
Get alerts when payers change rules like this one
We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.